10 September 2018
A new visiongain report forecasts that the global breast cancer drugs market will generate $19.96 billion in 2020. That revenue forecast and many others appear in Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals, published in March 2016. Visiongain is a business information publisher and consultancy based in London, UK.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Breast cancer is the second most common cancer in the world, and by far the most common cancer among women. With the prevalence of the disease set to increase, a strong pipeline waiting to be launched, and the rising use of combination therapies to benefit both patients and manufacturers, we expect strong growth for this lucrative market.
“However, the breast cancer drugs market will also have to face patent expiries for various leading therapies during the forecast period and the looming threat of generic and biosimilar erosion, amongst other difficult challenges. As such, 2016-2026 is a crucial period for this market, one which will determine its long term future.”
Visiongain’s new analysis provides revenue forecasts for the global breast cancer drugs market from 2016 to 2026.
That study also gives revenue forecasts, specifically for the breast cancer indication, for nine leading drugs from 2016 to 2026:
• Herceptin (trastuzumab), Roche
• Perjeta (pertuzumab), Roche
• Afinitor (everolimus), Novartis
• Faslodex (fulvestrant), AstraZeneca
• Ibrance (palbociclib), Pfizer
• Avastin (bevacizumab), Roche
• Kadcyla (ado-trastuzumab emtansine), Roche
• Femara (letrozole), Novartis
• Abraxane (paclitaxel Protein-Bound), Celgene.
That investigation also provides overall forecasts for two classes of biosimilar: trastuzumab and bevacizumab.
The report also divides the overall market into its main therapeutic segments, showing revenue forecasts from 2016 to 2026 for these four submarkets:
• Monoclonal antibodies (mAbs)
• Chemotherapy and hormone therapy
• Kinase inhibitors
• Other medicines.
That work also assesses the current status of 18 of the most promising candidates in research and development. It also shows interviews with two companies. In addition, visiongain’s study provides revenue forecasts for 11 national breast cancer drug markets:
• The United States
• Germany, France, Italy, the United Kingdom and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).
Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.
Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade.
19 February 2020
The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.
17 February 2020
Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.
17 February 2020
Global clinical research organizations market was valued at $34.9 billion in 2019 and is projected to grow at a CAGR of 9.5% during the forecast period 2020-2030.